Celldex Therapeutics (CLDX) Reports In-Line Q2 EPS

Celldex Therapeutics (NASDAQ: CLDX) reported Q2 EPS of ($0.32), in-line with the analyst estimate of ($0.32). Revenue for the quarter came in at $592 thousand versus the consensus estimate of $340 thousand.

For earnings history and earnings-related data on Celldex Therapeutics (CLDX) click here.

You May Also Be Interested In

• UBS sees a negative catalyst ahead for Nike: Here’s what to watch
• Lennar Corp. (LEN) Misses Q3 EPS by 10c
• Intuit holds investor day, reaffirms fiscal 2027 guidance